BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34393429)

  • 1. Molecular docking analysis of pyruvate kinase M2 with a potential inhibitor from the ZINC database.
    Sharma P; Singh M; Sharma S
    Bioinformation; 2021; 17(1):139-146. PubMed ID: 34393429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Nail Oncometabolite SAICAR in Oral Cancer Patients and Its Molecular Interactions with PKM2 Enzyme.
    Patel R; Raj AK; Lokhande KB; Almasri MA; Alzahrani KJ; Almeslet AS; Swamy KV; Sarode GS; Sarode SC; Patil S; Sharma NK
    Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC).
    Li RZ; Fan XX; Shi DF; Zhu GY; Wang YW; Luo LX; Pan HD; Yao XJ; Leung EL; Liu L
    Chem Biol Drug Des; 2018 Nov; 92(5):1851-1858. PubMed ID: 29931766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
    Ning X; Qi H; Li R; Li Y; Jin Y; McNutt MA; Liu J; Yin Y
    Eur J Med Chem; 2017 Sep; 138():343-352. PubMed ID: 28688274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.
    Matsui Y; Yasumatsu I; Asahi T; Kitamura T; Kanai K; Ubukata O; Hayasaka H; Takaishi S; Hanzawa H; Katakura S
    Bioorg Med Chem; 2017 Jul; 25(13):3540-3546. PubMed ID: 28511909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2).
    Xu Y; Liu XH; Saunders M; Pearce S; Foulks JM; Parnell KM; Clifford A; Nix RN; Bullough J; Hendrickson TF; Wright K; McCullar MV; Kanner SB; Ho KK
    Bioorg Med Chem Lett; 2014 Jan; 24(2):515-9. PubMed ID: 24374270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform.
    Ning X; Qi H; Li R; Jin Y; McNutt MA; Yin Y
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):126-129. PubMed ID: 29185365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators.
    Li R; Ning X; Zhou S; Lin Z; Wu X; Chen H; Bai X; Wang X; Ge Z; Li R; Yin Y
    Eur J Med Chem; 2018 Jan; 143():48-65. PubMed ID: 29172082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Succinyl-5-aminoimidazole-4-carboxamide-1-ribose 5'-Phosphate (SAICAR) Activates Pyruvate Kinase Isoform M2 (PKM2) in Its Dimeric Form.
    Yan M; Chakravarthy S; Tokuda JM; Pollack L; Bowman GD; Lee YS
    Biochemistry; 2016 Aug; 55(33):4731-6. PubMed ID: 27481063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds.
    Zhang Y; Liu B; Wu X; Li R; Ning X; Liu Y; Liu Z; Ge Z; Li R; Yin Y
    Bioorg Med Chem; 2015 Aug; 23(15):4815-4823. PubMed ID: 26081759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis.
    Zahra K; Dey T; Ashish ; Mishra SP; Pandey U
    Front Oncol; 2020; 10():159. PubMed ID: 32195169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyruvate kinase M2 at a glance.
    Yang W; Lu Z
    J Cell Sci; 2015 May; 128(9):1655-60. PubMed ID: 25770102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2.
    Shen Y; Chen M; Huang S; Zou X
    Oncol Lett; 2016 Jan; 11(1):717-722. PubMed ID: 26870273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor pyruvate kinase M2: A promising molecular target of gastrointestinal cancer.
    Guo C; Li G; Hou J; Deng X; Ao S; Li Z; Lyu G
    Chin J Cancer Res; 2018 Dec; 30(6):669-676. PubMed ID: 30700935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posttranslational Modifications of Pyruvate Kinase M2: Tweaks that Benefit Cancer.
    Prakasam G; Iqbal MA; Bamezai RNK; Mazurek S
    Front Oncol; 2018; 8():22. PubMed ID: 29468140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoform switch of pyruvate kinase M1 indeed occurs but not to pyruvate kinase M2 in human tumorigenesis.
    Zhan C; Yan L; Wang L; Ma J; Jiang W; Zhang Y; Shi Y; Wang Q
    PLoS One; 2015; 10(3):e0118663. PubMed ID: 25738776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1α and Bcl-xL in culture.
    Dong T; Yan Y; Chai H; Chen S; Xiong X; Sun D; Yu Y; Deng L; Cheng F
    Biomed Pharmacother; 2015 Feb; 69():277-84. PubMed ID: 25661370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors.
    Ye X; Sun Y; Xu Y; Chen Z; Lu S
    Med Chem; 2016; 12(7):613-620. PubMed ID: 26951145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase.
    Yacovan A; Ozeri R; Kehat T; Mirilashvili S; Sherman D; Aizikovich A; Shitrit A; Ben-Zeev E; Schutz N; Bohana-Kashtan O; Konson A; Behar V; Becker OM
    Bioorg Med Chem Lett; 2012 Oct; 22(20):6460-8. PubMed ID: 22963766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of the M2 Isoform of Pyruvate Kinase (PKM2) with shRNA Enhances the Effect of Docetaxel in Human NSCLC Cell Lines In Vitro.
    Yuan S; Qiao T; Zhuang X; Chen W; Xing N; Zhang Q
    Yonsei Med J; 2016 Nov; 57(6):1312-23. PubMed ID: 27593857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.